Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17971808 | 0.93 | — | — | |
| SCHEMBL9232446 | 0.84 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1MAPTSLC18A3GAA | |
| SCHEMBL21179109 | 0.80 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1MAPTSLC18A3 | |
| SCHEMBL13799456 | 0.76 | SLC6A4 (0.34) | SLC6A4SLC6A3GAA | |
| SCHEMBL7144406 | 0.76 | SLC6A4 (0.35) | MAPTSLC6A4SLC6A3 | |
| SCHEMBL10046778 | 0.75 | CYP3A4 (0.39) | ALDH1A1MAPT | |
| SCHEMBL14594772 | 0.75 | ALDH1A1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL25973884 | 0.73 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL27705534 | 0.73 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL21179111 | 0.72 | SLC6A4 (0.33) | MAPTSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | ALDH1A1 2657/4885L3MBTL1 4203/4885MAPT 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.